The Kruskal-Wallis ANOVA was used to detect differences between groups in [DELTA](delta) pain-free walking distance on the treadmill exercise test (pre-treatment to post-treatment) and [DELTA] pain-free walking distance on the 6-minute walk test (pretreatment to post-treatment), as these data were not normally distributed.
Pain-free walking distance during the SMWT increased significantly in the CER and UBST groups compared with the CONT group after training (37 [+ or -] 47% v.
Maximum walking distance, pain-free walking distance and total pain during the graded treadmill exercise test on entry to the study and after 6 weeks of intervention (mean [+ or -] SD) UBST (N=9) 0 wks 6 wks Body mass (kg) 78.
A total of 44% of the patients treated with beraprost had a positive response to treatment, defined as a 50% or greater improvement in pain-free walking distance, compared with baseline, and no cardiovascular events.
The primary endpoint of the study was met, with significantly more patients receiving VasoCare(TM) therapy having a greater than 50% increase in their pain-free walking distance (ICD) compared to placebo, at 24 weeks.
Examination of secondary endpoints in the severe claudication sub-group at nine weeks post-treatment indicated a substantial increase in both the median pain-free walking distance (ICD) and the median maximum walking distance (ACD).